Brief: Otsuka and Lundbeck announce top-line results from two phase III clinical trials
02/05/2017 08:10
May 2 (Reuters) - H LUNDBECK A/S LUN.CO
* OTSUKA 4578.T AND LUNDBECK ANNOUNCE IMPROVEMENT OF AGITATION SYMPTOMS RELATED TO
ALZHEIMER'S-TYPE DEMENTIA FOLLOWING TREATMENT WITH BREXPIPRAZOLE RELATIVE TO PLACEBO
* IN BOTH STUDIES, PATIENTS TREATED WITH BREXPIPRAZOLE SHOWED IMPROVEMENTS IN SYMPTOMS OF
AGITATION RELATIVE TO PLACEBO
Source text for Eikon: ID:nCSE6TJB
Further company coverage: LUN.CO
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com;))